These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 2791194)

  • 1. Ifosfamide cardiotoxicity in humans.
    Kandylis K; Vassilomanolakis M; Tsoussis S; Efremidis AP
    Cancer Chemother Pharmacol; 1989; 24(6):395-6. PubMed ID: 2791194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary excretion of ifosfamide, 4-hydroxyifosfamide, 3- and 2-dechloroethylifosfamide, mesna, and dimesna in patients on fractionated intravenous ifosfamide and concomitant mesna therapy.
    Kurowski V; Wagner T
    Cancer Chemother Pharmacol; 1997; 39(5):431-9. PubMed ID: 9054957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy.
    Andriole GL; Sandlund JT; Miser JS; Arasi V; Linehan M; Magrath IT
    J Clin Oncol; 1987 May; 5(5):799-803. PubMed ID: 3106585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (a Gynecologic Oncology Group study).
    Sutton GP; Blessing JA; Rosenshein N; Photopulos G; DiSaia PJ
    Am J Obstet Gynecol; 1989 Aug; 161(2):309-12. PubMed ID: 2548382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose ifosfamide and mesna in advanced breast cancer. A phase II study.
    Sanchiz F; Milla A
    Cancer Chemother Pharmacol; 1990; 26 Suppl():S91-2. PubMed ID: 2112057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unique alterations of thyroid function parameters after i.v. administration of alkylating drugs (cyclophosphamide and ifosfamide).
    Reinhardt W; Sauter V; Jockenhövel F; Kummer G; Uppenkamp M; Witzke O; Philipp T; Reinwein D; Mann K
    Exp Clin Endocrinol Diabetes; 1999; 107(3):177-82. PubMed ID: 10376442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase I trial of ifosfamide and paclitaxel with granulocyte-colony stimulating factor in the treatment of patients with refractory solid tumors.
    Bunnell CA; Thompson L; Buswell L; Berkowitz R; Muto M; Sheets E; Shulman LN
    Cancer; 1998 Feb; 82(3):561-6. PubMed ID: 9452275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ifosfamide, mitomycin and radiotherapy in non-small-cell lung cancer.
    Chetiyawardana SD; Cullen MH; Joshi RC; Woodroffe CM
    Cancer Chemother Pharmacol; 1989; 24(2):102-4. PubMed ID: 2543511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose ifosfamide is associated with severe, reversible cardiac dysfunction.
    Quezado ZM; Wilson WH; Cunnion RE; Parker MM; Reda D; Bryant G; Ognibene FP
    Ann Intern Med; 1993 Jan; 118(1):31-6. PubMed ID: 8416155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ifosfamide combination regimens for soft-tissue sarcoma.
    Stuart-Harris R; Dalley D; Bell DR; Levi J; Simes RJ; Wiltshaw E
    Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S185-8. PubMed ID: 8453695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of dose-escalated paclitaxel and carboplatin in combination with ifosfamide and filgrastim: preliminary results.
    Palackdharry CS
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):78-83. PubMed ID: 8677455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ambulatory high-dose 5-day continuous-infusion ifosfamide combination chemotherapy in advanced solid tumors: a feasibility study.
    Loeffler TM; Weber FW; Hausamen TU
    J Cancer Res Clin Oncol; 1991; 117 Suppl 4():S125-8. PubMed ID: 1795000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose ifosfamide by infusion with Mesna in advanced refractory sarcomas.
    Güllü I; Yalçin S; Tekuzman G; Barişta I; Alkiş N; Celik I; Zengin N; Güler N; Kars A; Baltali E
    Cancer Invest; 1996; 14(3):239-42. PubMed ID: 8630686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplatin as salvage therapy for relapsing and/or refractory lymphomas.
    Romaguera JE; Rodriguez MA; Hagemeister FB; McLaughlin P; Swan F; Moore DF; Sarris AH; Younes A; Hill D; Cabanillas F
    Invest New Drugs; 1994; 12(3):217-22. PubMed ID: 7896540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dosing and side-effects of ifosfamide plus mesna.
    Brade WP; Herdrich K; Kachel-Fischer U; Araujo CE
    J Cancer Res Clin Oncol; 1991; 117 Suppl 4():S164-86. PubMed ID: 1795007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe renal failure following high-dose ifosfamide and mesna.
    Willemse PH; de Jong PE; Elema JD; Mulder NH
    Cancer Chemother Pharmacol; 1989; 23(5):329-30. PubMed ID: 2495864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ifosfamide with mesna uroprotection and etoposide in recurrent, refractory acute leukemia in childhood. A Pediatric Oncology Group Study.
    Bernstein ML; Whitehead VM; Devine S; Grier H; Kung F; Krischer J; Dreyer Z; Bell B; Land V; Buchanan GR
    Cancer; 1993 Sep; 72(5):1790-4. PubMed ID: 8348510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of ifosfamide plus mesna as first-line chemotherapy in women with metastatic breast cancer.
    Ingle JN; Krook JE; Mailliard JA; Hartmann LC; Wieand HS
    Am J Clin Oncol; 1995 Dec; 18(6):498-501. PubMed ID: 8526193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination chemotherapy using vincristine, adriamycin, cyclophosphamide (VAC) alternating with ifosfamide and etoposide (IE) for advanced soft tissue sarcomas: a phase II study.
    Palumbo R; Palmeri S; Gatti C; Villani G; Cesca A; Toma S
    Oncol Rep; 1998; 5(1):69-72. PubMed ID: 9458296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group Study.
    Sutton GP; Blessing JA; Homesley HD; Berman ML; Malfetano J
    J Clin Oncol; 1989 Nov; 7(11):1672-6. PubMed ID: 2509641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.